Antidepressants and body weight: A comprehensive review and meta-analysis

Journal of Clinical Psychiatry

Volumn 71, Issue 10, 2010, Pages 1259-1272

  Serretti, Alessandro ^a   Mandelli, Laura ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BODY WEIGHT; HUMAN; METHODOLOGY; OBESITY; PRIORITY JOURNAL; PUBLISHING; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; HUMANS; TIME FACTORS; WEIGHT GAIN; WEIGHT LOSS;

EID: 78149305142     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09r05346blu     Document Type: Review

References (158)

1. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/ obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry. 2006;14(4):212-222. doi:10.1080/10673206089256 PubMed
2. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63(3): 207-213. PubMed
3. Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry. 2001;62(suppl 23):13-22. PubMed
4. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature. 2000;404(6778):672-677. PubMed
5. Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci. 1987;499(1 Human Obesity):203-215. doi:10.1/j.1749-632.1987.tb36212.x PubMed
6. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69(suppl E1):8-13. PubMed
7. Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav. 2007;92(1-2): 263-271. doi:10.1016/j.physbeh.207.05.021 PubMed
8. Hansen DG, Søndergaard J, Vach W, et al. Antidepressant drug use in general practice: inter-practice variation and association with practice characteristics. Eur J Clin Pharmacol. 2003;59(2):143-149. PubMed
9. Ufer M, Meyer SA, Junge O, et al. Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription-based analysis. Pharmacoepidemiol Drug Saf. 2007;16(10): 1153-1160. doi:10.102/pds.1405 PubMed
10. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156(11):1686-1696. PubMed
11. Munafò MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20(9):439-444. doi:10.1016/j.tig.204.06.014 PubMed
12. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533-1537. PubMed
13. Egger M, Juni P, Bartlett C, et al. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? empirical study. Health Technol Assess. 2003;7(1):1-76. PubMed
14. Rosenthal R. Meta-Analytic Procedures for Social Research. Newbury Park, CA: Sage Publications; 1991.
15. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3): 259-266. doi:10.1097/JCP.0b013e3181a523f PubMed
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. doi:10.1016/0197-2456(95)0134-4 PubMed
17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. PubMed
18. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119-1129. doi:10.1016/S0895-4356(0)0242-0 PubMed
19. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv. 2002;53(7):842-847. doi:10.176/api.ps.53.7.842 PubMed
20. Schatzberg A, Cole J, DeBattista C. Manual of Clinical Psychopharmacology. Washington, DC: American Psychiatric Pub.; 2007.
21. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002;17(suppl 1):S37-S41. doi:10.102/hup.38 PubMed
22. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249-264. PubMed
23. Leibowitz SF. The role of serotonin in eating disorders. Drugs. 1990; 39(suppl 3):33-48. doi:10.2165/03495-190393-05 PubMed
24. Brambilla P, Cipriani A, Hotopf M, et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38(2): 69-77. doi:10.105/s-205-837806 PubMed
25. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156(8): 1170-1176. PubMed
26. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000; 61(suppl 11):37-41. PubMed
27. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther. 2007; 113(1):134-153. doi:10.1016/j.pharmthera.206.07.02 PubMed
28. Albers L, Hahn R, Reist C. Handbook of Psychiatric Drugs. Laguna Hills, CA: Current Clinical Strategies Publishing, Inc; 1998.
29. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol. 1991;6(suppl 2):47-56. doi:10.1097/04850-191202-07 PubMed
30. Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol. 2000;23(2):90-97. doi:10.1097/02826-2030-06 PubMed
31. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14(3):175-182. doi:10.3109/10401230209147454 PubMed
32. Gupta RK, Tiller JW, Burrows GD. Dual action antidepressants and some important considerations. Aust N Z J Psychiatry. 2003;37(2): 190-195. doi:10.1046/j.140-1614.203.0169.x PubMed
33. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006;60(4):482-491. doi:10.1/j.1368-5031.206.0865.x PubMed
34. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005;20(5):327-341. doi:10.102/hup.696 PubMed
35. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003;9(1):97-140. PubMed
36. Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharmacokinet. 1993;25(2):103-114. doi:10.2165/0308-19325020-03 PubMed
37. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother. 2007;7(1):17-24. doi:10.1586/14737175.7.1.17 PubMed
38. Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68(5):653-689. doi:10.2165/03495-20868050-01 PubMed (Pubitemid 351484811)
39. Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6): 1021-1028. doi:10.1016/j.pnpbp.205.03.019 PubMed
40. Zimmermann U, Kraus T, Himmerich H, et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res. 2003;37(3):193-220. doi:10.1016/S02-3956(03)018-9 PubMed
41. Cipriani A, Malvini L, Furukawa TA, et al. Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates: systematic review, meta-analysis, and meta-regression analysis. J Clin Psychopharmacol. 2007;27(4):352-356. doi:10.1097/jcp.0b013e3180a9081f PubMed
42. De Fruyt J, Demyttenaere K. Quality of life measurement in antidepressant trials. Is there an added value? Psychother Psychosom. 2009;78(4): 212-219. doi:10.159/02142 PubMed
43. Sedman G. Trial of a sustained release form of amitriptyline (Lentizol) in the treatment of depressive illness. Br J Psychiatry. 1973;123(572): 69-71. doi:10.192/bjp.123.1.69 PubMed
44. Coppen A, Ghose K, Montgomery S, et al. Continuation therapy with amitriptyline in depression. Br J Psychiatry. 1978;133(1):28-33. doi:10.192/bjp.13.1.28 PubMed
45. Kupfer DJ, Coble PA, Rubinstein D. Changes in weight during treatment for depression. Psychosom Med. 1979;41(7):535-544. PubMed
46. Chouinard G. Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry. 1983;44(5 Pt 2):121-129. PubMed
47. Ravaris CL, Robinson DS, Ives JO, et al. Phenelzine and amitriptyline in the treatment of depression. A comparison of present and past studies. Arch Gen Psychiatry. 1980;37(9):1075-1080. PubMed
48. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998;13(2):63-73. doi:10.1097/04850-198030-02 PubMed
49. Remick RA, Campos PE, Misri S, et al. A comparison of the safety and efficacy of bupropion HCL and amitriptyline hcl in depressed outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4-6): 523-527. doi:10.1016/S0278- 5846(82)80143-7 PubMed
50. Maggioni F, Ruffatti S, Dainese F, et al. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain. 2005;6(4):322-324. doi:10.107/s10194-05-021-y PubMed
51. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985;46(3 Pt 2):32-37. PubMed
52. Hecht Orzack M, Cole JO, Friedman L, et al. Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiology. 1986;15(suppl 1):28-30. doi:10.159/018283 PubMed
53. Harris B, Young J, Hughes B. Comparative effects of seven antidepressant regimes on appetite, weight and carbohydrate preference. Br J Psychiatry. 1986;148(5):590-592. doi:10.192/bjp.148.5.590 PubMed
54. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res. 1988;26(3):265-271. doi:10.1016/0165-1781(8)90120-5 PubMed
55. Altamura AC, De Novellis F, Guercetti G, et al. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res. 1989;9(6):391-396. PubMed
56. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990;51(suppl B):28-33. PubMed
57. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990;51(suppl B):18-27. PubMed
58. Bakish D, Bradwejn J, Nair N, et al. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl). 1992;106(suppl):S98-S101. doi:10.107/BF0246248 PubMed
59. Beasley CM Jr, Sayler ME, Potvin JH. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int Clin Psychopharmacol. 1993;8(3):143-149. doi:10.1097/04850-1930830-02 PubMed
60. De Ronchi D, Rucci P, Lodi M, et al. Fluoxetine and amitriptyline in elderly depressed patients. a 10-week, double-blind study on course of neurocognitive adverse events and depressive symptoms. Arch Gerontol Geriatr. 1998;26(suppl 1):125-140. doi:10.1016/S0167-4943(98)8021-6
61. Sacchetti E, Cassano G, Penati G, et al. Paroxetine versus amitriptyline in patients with recurrent major depression: a double-blind trial. Int J Psychiatry Clin Pract. 2002;6(1):23-29. doi:10.1080/13651502753489380doi: 13651502753489380
62. Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia. 2005;25(11):1048-1053. doi:10.1/j.1468-2982.205.0956.x PubMed
63. Altintoprak AE, Zorlu N, Coskunol H, et al. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. Hum Psychopharmacol. 2008;23(4):313-319. doi:10.102/hup.935 PubMed
64. Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry. 1984;45(10):414-419. PubMed
65. Frank E, Kupfer DJ, Bulik CM, et al. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord. 1990;20(3): 165-172. doi:10.1016/0165-0327(90)90140-4 PubMed (Pubitemid 20350928)
66. Frank E, Kupfer DJ, Buhari A, et al. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord. 1992; 26(1):65-72. doi:10.1016/0165-0327(92)9036-6 PubMed
67. Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 1992;49(4):318-323. PubMed
68. Balon R, Yeragani VK, Pohl R, et al. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder. Can J Psychiatry. 1993;38(1):19-22. PubMed
69. Mavissakalian MR, Perel JM. The side effects burden of extended imipramine treatment of panic disorder. J Clin Psychopharmacol. 2000;20(5): 547-555. doi:10.1097/04714-2010-010 PubMed
70. Shioiri T, Kato T, Murashita J, et al. Changes in the frequency distribution pattern of body weight in patients with major depression. Acta Psychiatr Scand. 1993;88(5):356-360. doi:10.1/j.160-047.193.tb03472.x PubMed
71. Mavissakalian M, Perel J, Guo S. Specific side effects of long-term imipramine management of panic disorder. J Clin Psychopharmacol. 2002;22(2): 155-161. doi:10.1097/04714-202040-08 PubMed
72. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995;38(9):592-602. doi:10.1016/06-323(95)0178-8 PubMed
73. Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry. 2003;15(3-4):171-180. PubMed
74. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand. 2001; 104(2):104-109. doi:10.1034/j.160-047.201.0240.x PubMed
75. Moosa MY, Panz VR, Jeenah FY, et al. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol. 2003;23(6):549-552. doi:10.1097/01.jcp.095341.32154.8f PubMed
76. Beaumont G. An investigation into the short-term effects of clomipramine (Anafranil) administered in low doses, on weight. J Int Med Res. 1977;5(suppl):32-36. PubMed
77. Maina G, Albert U, Salvi V, et al. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(10):1365-1371. doi:10.408/JCP.v65n101 PubMed
78. Guelfi JD, Payan C, Fermanian J, et al. Moclobemide versus clomipramine in endogenous depression: a double-blind randomised clinical trial. Br J Psychiatry. 1992;160(4):519-524. doi:10.192/bjp.160.4.519 PubMed
79. Miller MD, Pollock BG, Rifai AH, et al. Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Geriatr Psychiatry Neurol. 1991;4(4):226-230. doi:10.17/089198791040409 PubMed
80. Weber E, Stack J, Pollock BG, et al; Reynolds CF3rd. Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial. Am J Geriatr Psychiatry. 2000;8(3):245-250. PubMed
81. Paradis CF, Stack JA, George CJ, et al. Nortriptyline and weight change in depressed patients over 60. J Clin Psychopharmacol. 1992;12(4):246-250. doi:10.1097/04714-192080-06 PubMed
82. Gendall KA, Joyce PR, Mulder RT, et al. The effects of fluoxetine versus nortriptyline on body weight in depression. J Clin Psychopharmacol. 2000;20(6):714-715. doi:10.1097/04714-20120-028 PubMed
83. Reynolds CF 3rd, Perel JM, Frank E, et al. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry. 1999;156(8):1177-1181. PubMed
84. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157(3):351-359. doi:10.176/api.ajp.157.3.351 PubMed
85. Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry. 1987;48(1):27-28. PubMed
86. Stern SL, Cooper TB, Johnson MH, et al. Lack of weight gain under desipramine. Biol Psychiatry. 1987;22(6):796-797. doi:10.1016/06-323(87)90217-4 PubMed
87. Leinonen E, Skarstein J, Behnke K, et al; Nordic Antidepressant Study Group. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol. 1999;14(6):329-337. doi:10.1097/04850-1910-02 PubMed
88. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a doubleblind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry. 2004;19(12):1123-1130. doi:10.102/gps.190 PubMed
89. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003;18(4):211-217. doi:10.1097/04850-203070-03 PubMed
90. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin. 2005;21(10):1659- 1668. doi:10.185/0307905X65484 PubMed
91. Dannon PN, Iancu I, Lowengrub K, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol. 2007;30(6):326-334. doi:10.1097/WNF. 0b013e318064579f PubMed
92. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50(1):57-64. doi:10.159/07825 PubMed
93. Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2005;66(11):1441-1446. doi:10.408/JCP.v6n15 PubMed (Pubitemid 41779543)
94. Muller JE, Wentzel I, Koen L, et al. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(1):43-48. doi:10.1097/YIC.0b013e32825ea301 PubMed
95. Kasper S, Lemming OM, de Swart H. Escitalopram in the longterm treatment of major depressive disorder in elderly patients. Neuropsychobiology. 2006;54(3):152-159. doi:10.159/098650 PubMed
96. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry. 2006;21(6):367-378. doi:10.1016/j.eurpsy.206.03.04 PubMed
97. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin. 2007;23(6):1303-1318. doi:10.185/0307907X18107 PubMed
98. Levine R, Hoffman JS, Knepple ED, et al. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients. J Clin Psychopharmacol. 1989;9(4):281-283. doi:10.1097/04714-1989080-08 PubMed
99. Orzack MH, Friedman LM, Marby DW. Weight changes on fluoxetine as a function of baseline weight in depressed outpatients. Psychopharmacol Bull. 1990;26(3):327-330. PubMed
100. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry. 1985;46(3 Pt 2):26-31. PubMed
101. Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Br J Psychiatry. 1987;150(5):653-655. doi:10.192/bjp.150.5.653 PubMed
102. Muijen M, Roy D, Silverstone T, et al. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand. 1988;78(3):384-390. doi:10.1/j.160-047.198.tb06353.x PubMed
103. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007;68(8):1246-1256. doi:10.408/JCP.v68n0812 PubMed
104. Corne SJ, Hall JR. A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. Int Clin Psychopharmacol. 1989;4(3):245-254. doi:10.1097/04850-1989070-07 PubMed
105. Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry. 1990; 51(1):8-11. PubMed
106. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry. 1991;24(2):62-67. doi:10.105/s-207-10140 PubMed
107. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991;52(8):329-335. PubMed
108. Goldstein DJ, Hamilton SH, Masica DN, et al. Fluoxetine in medically stable, depressed geriatric patients: effects on weight. J Clin Psychopharmacol. 1997;17(5):365-369. doi:10.1097/04714-19710-05 PubMed
109. Falk WE, Rosenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol. 1989;2(4): 208-214. doi:10.17/089198789020407 PubMed
110. Guelfi JD, Ansseau M, Corruble E, et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol. 1998;13(3):121-128. doi:10.1097/04850-198050-05 PubMed
111. Wheatley DP, van Moffaert M, Timmerman L, et al; Mirtazapine- Fluoxetine Study Group. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry. 1998;59(6):306-312. PubMed
112. Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry. 1999;7(3):221-227. doi:10.1097/01942-19080-06 PubMed
113. Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry. 2000;61(8):559-568. PubMed
114. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63(3):225-231. PubMed
115. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65(7):903-907. doi:10.408/JCP.v65n0704 PubMed
116. Papakostas GI, Petersen T, Iosifescu DV, et al. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005;8(1):59-63. doi:10.1017/S14614570404602 PubMed
117. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al; Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137-146. doi:10.2165/023210-20519020-04 PubMed
118. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211-215. doi:10.1016/j.biopsych.205.07.05 PubMed
119. Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24(2):118-125. doi:10.1097/01.jcp.01062.3634.96 PubMed
120. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebocontrolled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004; 24(1):49-55. doi:10.1097/01.jcp.0104906.75206.8b PubMed
121. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61(9):656-663. PubMed
122. Dannon PN, Iancu I, Cohen A, et al. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry. 2004;4(1):16. doi:10.186/1471-24X-4-16 PubMed
123. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000;61(3):196-202. PubMed
124. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14(6): 457-470. doi:10.1016/j.euroneuro.204.01.02 PubMed
125. Hinze-Selch D, Schuld A, Kraus T, et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology. 2000;23(1):13-19. doi:10.1016/S0893-13X(0)089-0 PubMed
126. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol. 2000;20(6):645-652. doi:10.1097/04714-20120-010 PubMed
127. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24(4):389-399. doi:10.1097/01.jcp.013248.65972.d9 PubMed
128. Lee P, Shu L, Xu X, et al. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci. 2007;61(3):295-307. doi:10.1/j.140-1819.207.016.x PubMed
129. Goldberg RJ. Weight change in depressed nursing home patients on mirtazapine. J Am Geriatr Soc. 2002;50(8):1461. doi:10.1046/j.1532-5415.202. 50374.x PubMed
130. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry. 1999;11(4):205-215. doi:10.3109/1040123909147072 PubMed
131. Croft H, Settle E Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained- release bupropion and sertraline. Clin Ther. 1999;21(4): 643-658. doi:10.1016/S0149-2918(0)8317-4 PubMed
132. Kraus T, Haack M, Schuld A, et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry. 2002;35(6):220-225. doi:10.105/s-202-36390 PubMed
133. Emslie GJ, Yeung PP, Kunz NR. Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder. CNS Spectr. 2007;12(3):223-233. PubMed
134. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008;42(1):22-34. doi:10.1016/j. jpsychires.207.01.08 PubMed
135. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002; 36(4):106-132. PubMed
136. Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care. 2007;30(1): 21-26. doi:10.237/dc06-0947 PubMed
137. Wohlreich MM, Martinez JM, Mallinckrodt CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol. 2005;25(6):552-560. doi:10.1097/01.jcp.0185429.1053.c8 PubMed
138. Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety. 2007;24(1):41-52. doi:10.102/da.20209 PubMed
139. Dunner DL, Wilson M, Fava M, et al. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety. 2008;25(5):E1-E8. doi:10.102/da.2039 PubMed
140. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol. 2008;28(1):32-38. doi:10.1097/jcp. 0b013e318160738e PubMed
141. Halikas JA. A randomized, double-blind, placebo-controlled, 5 week's study of Org 3770 (mirtazapine) in major depression: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol. 1995; 10(suppl 2):S125-S133.
142. Thase ME, Nierenberg AA, Keller MB, et al; Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry. 2001;62(10):782-788. PubMed
143. Wålinder J, Prochazka J, Odén A, et al. Mirtazapine naturalistic depression study (in Sweden) - MINDS(S): clinical efficacy and safety. Hum Psychopharmacol. 2006;21(3):151-158. doi:10.102/hup.753 PubMed
144. Boshuisen ML, Slaap BR, Vester-Blokland ED, et al. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol. 2001;16(6):363-368. doi:10.1097/04850-2010-08 PubMed
145. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002;23(5):442-447. doi:10.1016/S085-3924(02)0381-0 PubMed
146. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry. 2003;64(8): 883-889. doi:10.408/JCP.v64n0805 PubMed
147. Roose SP, Nelson JC, Salzman C, et al; Mirtazapine in the Nursing Home Study Group. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Curr Med Res Opin. 2003;19(8):737-746. doi:10.185/03079031250241 PubMed
148. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006;29(1):170-171. doi:10.237/diacare.29.1.170 PubMed
149. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006;67(3):421-424. doi:10.408/JCP.v67n0313 PubMed
150. Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEXCRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31(4):832-844. doi:10.1038/sj.np.130923 PubMed
151. Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther. 2002;24(4):662-672. doi:10.1016/S0149-2918(02)85141-4 PubMed
152. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14(3):170-179. doi:10.1097/04714-194060-04 PubMed
153. Reimherr FW, Cunningham LA, Batey SR, et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther. 1998;20(3):505-516. doi:10.1016/S0149-2918(98)8060-X PubMed
154. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999;21(3):454-463. doi:10.1016/S0149-2918(0)8301-0 PubMed
155. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(6): 865-873. doi:10.408/JCP.v67n0602 PubMed
156. Moll E, Neumann N, Schmid-Burgk W, et al. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol. 1994;17(suppl 1):S74-S87. PubMed
157. Gagiano CA, Hart GA, Bodemer W, et al. Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules. Clin Neuropharmacol. 1994;17(suppl 1):S1-S8. PubMed
158. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol. 1997;7(suppl 1):S37-S47.